三生制药:天价DEAL刷记录 临床开发再加速

中泰证券
23 May

事件:5 月20 日公司公告,与辉瑞就PD1×VEGF 双抗SSGJ707 签订授权许可协议,授予对方在全球(除外中国大陆)开发、生产、商业化的权益。公司将收到合作方辉瑞支付的12.5 亿美元首付款,潜在48 亿美元开发、监管和销售里程碑,及净销售额双位数的特许分成。该首付款金额12.5 亿美金为中国创新药Lisence out 之最,再次刷新记录。PD1×VEGF 双抗赛道再验证,SSGJ707...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10